SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Silk Road Medical, Inc (SILK) .
Criteria proven by this page:
- VALUE (60/100, Pass) — analyst target implies upside (+11.2%).
- Analyst consensus target $30.58 (+11.2% upside) — modest upside expected.
Overall SharesGrow Score: 41/100 with 1/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
60/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — SILK
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio6.02
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.44
Book Value / Share$0.00
Revenue / Share$4.56
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$30.58 (+11.2%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2017 |
$-0.80 |
$14.26M |
$-19.36M |
-135.8% |
| 2018 |
$-1.31 |
$34.56M |
$-37.63M |
-108.9% |
| 2019 |
$-2.44 |
$63.35M |
$-56.07M |
-88.5% |
| 2020 |
$-1.53 |
$75.23M |
$-50.39M |
-67% |
| 2021 |
$-1.45 |
$101.48M |
$-50.39M |
-49.7% |
| 2022 |
$-1.62 |
$138.64M |
$-58.02M |
-41.8% |
| 2023 |
$-1.44 |
$177.13M |
$-55.74M |
-31.5% |
